Infectious Disease

Infectious disease antibodies bind viral envelope proteins or bacterial toxins for neutralization and infection studies. Sotrovimab, casirivimab and bamlanivimab bind the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Palivizumab and nirsevimab neutralize respiratory syncytial virus (RSV) by binding its fusion protein. Bezlotoxumab binds Clostridioides difficile toxin B, while raxibacumab and obiltoxaximab neutralize the protective antigen of anthrax toxin. Further antibodies target human immunodeficiency virus (HIV), influenza, hepatitis B virus and Ebola virus glycoproteins, as well as cytomegalovirus and BK virus.

2 Items

  • Gedivumab — antibody illustration
    Cat. No.
    AT0317

    Gedivumab

    Synonyms: MHAA4549A; RG7745

    Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody engineered to target the influenza A virus (IAV) with high specificity. It binds to the highly conserved stem region of the IAV hemagglutinin protein. This interaction inhibits hemagglutinin maturation and blocks hemagglutinin-mediated membrane fusion within the intranucleosome. Gedivumab is an essential tool for research in IAV infection disease studies, offering potential insights into viral entry mechanisms and the development of antiviral therapies.

    1 mg
    $240.00
    5 mg
    $624.00
    All 3 sizes
  • Vecantoxatug — antibody illustration
    Cat. No.
    AT1040

    Vecantoxatug

    Vecantoxatug is a humanized monoclonal antibody designed to target the Clostridium tetani toxin (TeNT, neurotoxin). By specifically binding to this toxin, Vecantoxatug inhibits its interaction with cellular receptors, effectively neutralizing its toxic effects. This antibody is particularly valuable for research focused on tetanus, offering potential insights into toxin mechanism and therapeutic interventions.

    1 mg
    $450.00
    5 mg
    $1,400.00
    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...